Urinary TIMP-2·IGFBP7: meta-analysis supports early detection of AKI

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) may represent a reliable biomarker for early detection of acute kidney injury (AKI).

Why this matters

  • The test is relatively new, and its clinical utility remains unclear.

Study design

  • Systematic review and meta-analysis of 9 studies (n=1886); 4 in cardiac surgery patients, 4 in critically ill patients, and 1 in emergency department patients.
  • All defined AKI based on Kidney Disease: Improving Global Outcomes criteria; urinary TIMP-2·IGFBP7 measured using NephroCheck.
  • Funding: None.

Key results

  • TIMP-2·IGFBP7 diagnostic accuracy was fair, with a pooled sensitivity and specificity of 0.83 (95% CI, 0.75-0.89; I2, 79.87%) and 0.72 (95% CI, 0.56-0.84; I2, 95.38%), respectively; area under the summary receiver operating characteristic (SROC) curve was 0.86 (95% CI, 0.82-0.88).
  • Sensitivity and specificity for stage ≥2 AKI were 0.92 (95% CI, 0.81-0.96; I2, 73.45%) and 0.63 (95% CI, 0.49-0.74; I2, 94.70%), respectively; area under SROC curve was 0.88 (95% CI, 0.85-0.91).
  • Significant publication bias observed (P=.04).

Limitations

  • 3 studies had high-risk bias (1 in patient selection; 2 in flow/timing).
  • Significant heterogeneity.
  • Most of the patients were associated with 2 authors.
  • Key studies excluded because of inability to extract a 2×2 contingency table.